I saw someone tweet something about Roches IL-2 showing activity in monotherapy. I haven't seen the data though.
Should add that NKTR has a collaboration with SNDX (where they test 214 in combo with entinostat not a development license). Again I haven't looked at SNDX to see if its related or not.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.